Bracco Diagnostics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://imaging.bracco.com/us-en

Clinical Trials

Lumason® Infusion vs. Bolus Administrations

Phase 3

Not yet recruiting

Conditions: Heart Diseases

Interventions: Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
Drug: Lumason

First Posted Date: 2024-05-06

Last Posted Date: 2024-05-06

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 106

Registration Number: NCT06400004

Locations: 🇺🇸
Piedmont Heart Institute, Atlanta, Georgia, United States
🇺🇸
Oregon Health and Sciences University, Portland, Oregon, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Study With Oral Isovue in Abdominopelvic CT

Completed

Conditions: Patients Requiring Abdominopelvic CT With Oral Administration of Contrast

First Posted Date: 2020-07-01

Last Posted Date: 2023-02-08

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 218

Registration Number: NCT04453059

Locations: 🇺🇸
Akron Children's Hospital, Akron, Ohio, United States

Optimal Timing of BR55 CEUS of the Ovaries

Phase 2

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: BR55

First Posted Date: 2020-01-30

Last Posted Date: 2024-08-23

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 3

Registration Number: NCT04248153

Locations: 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States

Thyroid Function of Pediatric Subjects Following Isovue® Administration

Phase 4

Terminated

Conditions: Hypothyroidism

Interventions: Drug: Isovue

First Posted Date: 2018-12-19

Last Posted Date: 2025-01-13

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 17

Registration Number: NCT03779906

Locations: 🇺🇸
Children's Hospital and Medical Center, Omaha, Nebraska, United States

Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs

Completed

Conditions: Central Nervous System Diseases
Central Nervous System Neoplasms

First Posted Date: 2018-11-21

Last Posted Date: 2020-01-23

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 125

Registration Number: NCT03750188

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

BR55 in Characterization of Ovarian Lesions

Phase 2

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: BR55

First Posted Date: 2018-04-10

Last Posted Date: 2023-08-01

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 14

Registration Number: NCT03493464

Locations: 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States

Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions

Phase 2

Terminated

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: BR55

First Posted Date: 2018-04-03

Last Posted Date: 2024-08-23

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 4

Registration Number: NCT03486327

Locations: 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States

Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients

Completed

Conditions: Central Nervous System Diseases
Central Nervous System Neoplasms

Interventions: Drug: MultiHance

First Posted Date: 2017-05-10

Last Posted Date: 2018-07-18

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 352

Registration Number: NCT03147989

Locations: 🇺🇸
Sarasota Memorial Hospital, Sarasota, Florida, United States

Evaluation of Gd Retention in Human Bone and Skin After MultiHance or ProHance Administration Compared With Control

Completed

Conditions: Gadolinium Retention

Interventions: Procedure: Surgery

First Posted Date: 2017-04-11

Last Posted Date: 2020-08-14

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 28

Registration Number: NCT03108378

Locations: 🇺🇸
VA San Diego Healthcare System, San Diego, California, United States

A Multicenter Study of Iomeron®-400 Used With Multi-detector Computed Tomography Angiography (MDCTA)

Phase 4

Completed

Conditions: Peripheral Artery Disease
Aortic Disorders
Carotid Disease
Pulmonary Disease

Interventions: Other: Iomeron

First Posted Date: 2015-11-04

Last Posted Date: 2017-06-02

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 224

Registration Number: NCT02596048

Locations: 🇨🇳
Wuhan Union Hospital, Wuhan, Hubei, China
🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳
The First Teaching Hospital of Xinjiang Medical University, Wulumuqi, Xinjiang, China

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy